CareDx logo

CareDx

CDNA | NASDAQ
Chart Builder DCF Calculator
$73.72
-$4.16 (-5.34%)
At close: Nov 16, 2026, 4:00 PM ET
$73.69
-$0.03 (-0.04%)
After-hours: Nov 16, 2026, 7:49 PM ET
-5.34%

Rating

Updated: Nov 16, 2026
62.4
Fundamentals Strong
Market Sentiment Bullish
Moat Narrow
Sector Rank #113/1021 (Top 11%)

Key Statistics

Market Data

Market Cap $3.87B
1D Range
73.39 78.36
52W Range
15.51 88.47

Valuation (TTM)

PE 30.85
PB 8.29
EV/EBITDA 127.97

Valuation (NTM)

Forward PE 43.75
Forward PEG -0.04
Price Target $92.00
Loading financial charts...

Profile

CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare provider...

Sector Healthcare
Employees 763
IPO Date Jul 17, 2014
Fiscal Year January - December

Latest News

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

10 days ago · businesswire.com

CareDx Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CareDx (CDNA) Upgraded to Strong Buy: Here's What You Should Know

11 days ago · zacks.com

CareDx (CDNA) Upgraded to Strong Buy: Here's What You Should Know
CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth

14 days ago · zacks.com

CareDx Q3 Earnings Call Highlights Raised '26 Outlook & Testing Growth
CareDx Announces Third KOAR Analysis Published in Transplantation

14 days ago · businesswire.com

CareDx Announces Third KOAR Analysis Published in Transplantation
Why CareDx Stock Soared Today

17 days ago · fool.com

Why CareDx Stock Soared Today
CareDx, Inc. (CDNA) Q3 2026 Earnings Call Transcript

18 days ago · seekingalpha.com

CareDx, Inc. (CDNA) Q3 2026 Earnings Call Transcript
What CareDx (CDNA) Said on Its Q3 Earnings Call

18 days ago · marketbeat.com

What CareDx (CDNA) Said on Its Q3 Earnings Call
CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates

18 days ago · zacks.com

CareDx (CDNA) Surpasses Q3 Earnings and Revenue Estimates
CareDx to Report Q3 Earnings: Transplant Testing Growth in Focus

22 days ago · zacks.com

CareDx to Report Q3 Earnings: Transplant Testing Growth in Focus
CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026

26 days ago · businesswire.com

CareDx Announces New KOAR Data Linking Elevated AlloSure® Kidney to Nearly 3-Fold Higher Risk of Adverse Graft Outcomes in Patients with Borderline Rejection or TCMR at ASN Kidney Week 2026

Earnings

Latest Earnings
Oct 29, 2026
EPS
$0.7
Beat +174.73%
REV
$139.36M
Beat +14.27%
Next Earnings
Feb 23, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
4
Consensus
Hold
Price Target
$92.00
Upside
+24.80%
Buy (2)
Hold (2)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.